OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
APGAR ScoreAssisted Delivery (FIGO)BPP (Manning Score)Bishop ScoreCARPREG II Cardiac RiskCervical Cancer StagingContraceptive Pearl IndexDoppler Matrix (UA/MCA)EFW (Hadlock)Endometrial StagingEndometrial ThicknessFGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey ScoreFetal Anemia (MCA PSV)GDM Diagnostic CriteriaGPA History IndicatorGail Model Breast RiskGestational Dating (LMP)HIV PMTCT ProtocolIOTA Simple RulesIVF Due Date & AMHIron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS ClassificationOvarian Cancer StagingPAS Hemorrhage RiskPPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS CriteriaSyphilis ManagementTORCH FrameworkVBAC Success ProbabilityVulvar Cancer StagingWeight Gain (IOM)mWHO Cardiac Risk

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Calculation of total iron requirement in patients with Iron Deficiency Anemia (IDA).
  • Planning parenteral (IV) iron replacement therapy when oral iron is ineffective, not tolerated, or rapid replenishment is required.
  • Second or third trimester anemia where Hb < 10.5–11.0 g/dL and ferritin < 30 ng/mL.
  • Pre-operative optimization for patients with scheduled Cesarean sections and known anemia.

Clinical Thresholds in Pregnancy

Iron deficiency is typically defined as Ferritin < 30 ng/mL. In the presence of inflammation (elevated CRP), a threshold of < 100 ng/mL may be used, though this is less specific in the obstetric population.

CLINICAL INSIGHT

How it Works

The Ganzoni Formula

Parameter Definitions

Target Hb
Factor 0.24
Iron Stores

Weight Selection in Pregnancy

Use pre-pregnancy weight for the calculation. Using actual weight in late pregnancy may lead to iron overestimation/overload due to the significant portion of weight attributed to fetal/placental tissue and edema.

CLINICAL INSIGHT

Practical Pearls

Obstetric Considerations

  • IV iron is generally avoided in the 1st trimester (limited safety data); it is preferred in the 2nd and 3rd trimesters.
  • In pregnancy, many clinicians use a Target Hb of 12 g/dL rather than the 15 g/dL used in the original formula to avoid over-replacement.
  • The formula accounts for the "Iron Stores" depot (500mg), which is essential to prevent immediate recurrence of anemia after Hb correction.

Limitations

  • The Ganzoni formula is known to underestimate requirements in some populations; simplified dosing (e.g., 1000mg flat dose) is increasingly used for newer formulations.
  • Does not account for ongoing blood loss (e.g., placenta previa or GI bleeds).
  • Formula does not apply to non-iron deficiency anemias (e.g., B12 deficiency, Thalassemia).
CLINICAL INSIGHT

Next Steps

Administration Strategy

  • Verify Iron Deficiency: Confirm Ferritin < 30 ng/mL or Transferrin Saturation (TSAT) < 20%.
  • Select Formulation: Choose based on local formulary (e.g., Iron Sucrose, Ferric Carboxymaltose).
  • Dosing Schedule: If total deficit > maximum single dose (e.g., >1000mg for FCM), split into two sessions 7 days apart.
  • Monitoring: Recheck CBC and Ferritin 4–8 weeks post-infusion. Do not recheck within 2 weeks of infusion.

Safety Warning

Resuscitation equipment and trained staff must be available during infusions due to the risk (though rare with modern formulations) of hypersensitivity or anaphylactoid reactions.

CLINICAL INSIGHT

Evidence Base

Primary Reference

Intravenous iron-dextran: therapeutic and experimental possibilities.

Ganzoni AM.Schweiz Med Wochenschr.1970

Obstetric Validation

Intravenous iron sucrose v/s oral ferrous fumarate in treatment of anemia in pregnancy.

Bhavi SB, Jaju PB.J Obstet Gynaecol India.2017
CLINICAL INSIGHT

Background

Dr. Andreas M. Ganzoni

A Swiss hematologist who sought to provide a physiological basis for iron replacement. Before this formula, IV iron dosing was largely empirical and frequently resulted in either ineffective treatment or unnecessary toxicity.

Historical Context

The Ganzoni formula was developed in an era where Iron Dextran was the primary IV option. While newer compounds (like Ferric Carboxymaltose) have modified dosing logic, the Ganzoni equation remains the academic gold standard for calculating total body iron deficit.

Iron Deficit (Ganzoni)

Ganzoni Iron Deficit

Parenteral Iron Requirements

The factor 2.4 = 0.0034(iron content of Hb in %) × 0.07(blood volume as % of body weight) × 1000. 500mg represents average iron stores.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Calculation of total iron requirement in patients with Iron Deficiency Anemia (IDA).
  • Planning parenteral (IV) iron replacement therapy when oral iron is ineffective, not tolerated, or rapid replenishment is required.
  • Second or third trimester anemia where Hb < 10.5–11.0 g/dL and ferritin < 30 ng/mL.
  • Pre-operative optimization for patients with scheduled Cesarean sections and known anemia.

Clinical Thresholds in Pregnancy

Iron deficiency is typically defined as Ferritin < 30 ng/mL. In the presence of inflammation (elevated CRP), a threshold of < 100 ng/mL may be used, though this is less specific in the obstetric population.

CLINICAL INSIGHT

How it Works

The Ganzoni Formula

Parameter Definitions

Target Hb
Factor 0.24
Iron Stores

Weight Selection in Pregnancy

Use pre-pregnancy weight for the calculation. Using actual weight in late pregnancy may lead to iron overestimation/overload due to the significant portion of weight attributed to fetal/placental tissue and edema.

CLINICAL INSIGHT

Practical Pearls

Obstetric Considerations

  • IV iron is generally avoided in the 1st trimester (limited safety data); it is preferred in the 2nd and 3rd trimesters.
  • In pregnancy, many clinicians use a Target Hb of 12 g/dL rather than the 15 g/dL used in the original formula to avoid over-replacement.
  • The formula accounts for the "Iron Stores" depot (500mg), which is essential to prevent immediate recurrence of anemia after Hb correction.

Limitations

  • The Ganzoni formula is known to underestimate requirements in some populations; simplified dosing (e.g., 1000mg flat dose) is increasingly used for newer formulations.
  • Does not account for ongoing blood loss (e.g., placenta previa or GI bleeds).
  • Formula does not apply to non-iron deficiency anemias (e.g., B12 deficiency, Thalassemia).
CLINICAL INSIGHT

Next Steps

Administration Strategy

  • Verify Iron Deficiency: Confirm Ferritin < 30 ng/mL or Transferrin Saturation (TSAT) < 20%.
  • Select Formulation: Choose based on local formulary (e.g., Iron Sucrose, Ferric Carboxymaltose).
  • Dosing Schedule: If total deficit > maximum single dose (e.g., >1000mg for FCM), split into two sessions 7 days apart.
  • Monitoring: Recheck CBC and Ferritin 4–8 weeks post-infusion. Do not recheck within 2 weeks of infusion.

Safety Warning

Resuscitation equipment and trained staff must be available during infusions due to the risk (though rare with modern formulations) of hypersensitivity or anaphylactoid reactions.

CLINICAL INSIGHT

Evidence Base

Primary Reference

Intravenous iron-dextran: therapeutic and experimental possibilities.

Ganzoni AM.Schweiz Med Wochenschr.1970

Obstetric Validation

Intravenous iron sucrose v/s oral ferrous fumarate in treatment of anemia in pregnancy.

Bhavi SB, Jaju PB.J Obstet Gynaecol India.2017
CLINICAL INSIGHT

Background

Dr. Andreas M. Ganzoni

A Swiss hematologist who sought to provide a physiological basis for iron replacement. Before this formula, IV iron dosing was largely empirical and frequently resulted in either ineffective treatment or unnecessary toxicity.

Historical Context

The Ganzoni formula was developed in an era where Iron Dextran was the primary IV option. While newer compounds (like Ferric Carboxymaltose) have modified dosing logic, the Ganzoni equation remains the academic gold standard for calculating total body iron deficit.